Hengrui Pharma (600276.SH) announced that the company has received a Filing Communication from the U.S. Food and Drug Administration (FDA), indicating that its resubmitted Biologics License Application (BLA) for camrelizumab injection in combination with apatinib mesylate tablets as a first-line treatment for patients with unresectable or metastatic hepatocellular carcinoma has been accepted for review.
According to the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of July 23, 2026, for the review of camrelizumab injection.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments